MAPK signalling pathways as molecular targets for anti-inflammatory therapy—from molecular mechanisms to therapeutic benefits

Monaco, 2004, T-cell-mediated signalling in immune, inflammatory and angiogenic processes: the cascade of events leading to inflammatory diseases, Curr. Drugs Target Inflamm. Allergy, 3, 35, 10.2174/1568010043483881 Schwartsburd, 2003, Chronic inflammation as inductor of procancer microenvironment: pathogenesis of dysregulated feedback control, Cancer Metastasis Rev., 22, 95, 10.1023/A:1022220219975 Heller, 1997, Discovery and analysis of inflammatory disease-related genes using cDNA microarrays, Proc. Natl. Acad. Sci. U. S. A., 94, 2150, 10.1073/pnas.94.6.2150 Feldmann, 2003, TNF defined as a therapeutic target for rheumatoid arthritis and other autoimmune diseases, Nat. Med., 9, 1245, 10.1038/nm939 Sweeney, 2001, Signal transduction in rheumatoid arthritis, Curr. Opin. Rheumatol., 16, 231, 10.1097/00002281-200405000-00011 Kumar, 2001, Intracellular signaling pathways as a target for the treatment of rheumatoid arthritis, Curr. Opin. Pharmacol., 1, 307, 10.1016/S1471-4892(01)00054-6 Weinblatt, 1999, A trial of etanercept, a recombinant tumor necrosis factor receptor:Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate, N. Engl. J. Med., 340, 253, 10.1056/NEJM199901283400401 Williams, 1992, Anti-tumor necrosis factor ameliorates joint disease in murine collagen-induced arthritis, Proc. Natl. Acad. Sci. U. S. A., 89, 9784, 10.1073/pnas.89.20.9784 Feldmann, 2001, Anti-TNFα therapy of rheumatoid arthritis: what have we learned?, Annu. Rev. Immunol., 19, 163, 10.1146/annurev.immunol.19.1.163 Garces, 2001, Anakinra: interleukin-1 receptor antagonist therapy for rheumatoid arthritis, Issues Emerg. Health Technol., 16, 1 Van der Blink, 2002, From extracellular to intracellular targets, inhibiting MAP kinases in treatment of Crohn's disease, Ann. N. Y. Acad. Sci., 973, 349, 10.1111/j.1749-6632.2002.tb04664.x van Montfrans, 2002, Inflammatory signal transduction in Crohn's disease and novel therapeutic approaches, Biochem. Pharmacol., 64, 789, 10.1016/S0006-2952(02)01140-1 Van Deventer, 2002, Immunotherapy of Crohn's disease, Scand. J. Immunol., 51, 18, 10.1046/j.1365-3083.2000.00657.x Koistinaho, 2005, Interactions between Alzheimer's disease and cerebral ischemia—Focus on inflammation, Brain Res. Rev., 48, 240, 10.1016/j.brainresrev.2004.12.014 Danton, 2003, Inflammatory mechanisms after ischemia and stroke, J. Neuropathol. Exp. Neurol., 62, 127, 10.1093/jnen/62.2.127 Schwartz, 2003, Macrophages and microglia in central nervous system injury: are they helpful or harmful?, J. Cereb. Blood Flow. Metab., 23, 385, 10.1097/00004647-200304000-00001 Rothwell, 1999, Cytokines—killers in the brain?, J. Physiol., 514, 3, 10.1111/j.1469-7793.1999.003af.x Touzani, 1999, Potential mechanisms of interleukin-1 involvement in cerebral ischaemia, J. Neuroimmunol., 100, 203, 10.1016/S0165-5728(99)00202-7 Martin-Villalba, 1999, CD95 ligand (Fas-L/APO-1L) and tumor necrosis factor-related apoptosis-inducing ligand mediate ischemia-induced apoptosis in neurons, J. Neurosci., 19, 3809, 10.1523/JNEUROSCI.19-10-03809.1999 Barone, 1997, Tumor necrosis factor-alpha. A mediator of focal ischemic brain injury, Stroke, 28, 1233, 10.1161/01.STR.28.6.1233 Schielke, 1998, Reduced ischemic brain injury in interleukin-1 beta converting enzyme-deficient mice, J. Cereb. Blood Flow. Metab., 18, 180, 10.1097/00004647-199802000-00009 Boutin, 2001, Role of IL-1alpha and IL-1beta in ischemic brain damage, J. Neurosci., 21, 5528, 10.1523/JNEUROSCI.21-15-05528.2001 Huang, 1994, Effects of cerebral ischemia in mice deficient in neuronal nitric oxide synthase, Science, 265, 1883, 10.1126/science.7522345 Shohami, 1999, Dual role of tumor necrosis factor alpha in brain injury, Cytokine Growth Factor Rev., 10, 119, 10.1016/S1359-6101(99)00008-8 Stoll, 1998, Inflammation and glial responses in ischemic brain lesions, Prog. Neurobiol., 56, 149, 10.1016/S0301-0082(98)00034-3 Aggarwal, 2003, Signalling pathways of the TNF superfamily: a double-edged sword, Nat. Rev., Immunol., 9, 745, 10.1038/nri1184 Lee, 1996, Role of CSBP/p38/RK stress response kinase in LPS and cytokine signaling mechanisms, J. Leukoc. Biol., 59, 152, 10.1002/jlb.59.2.152 Kyriakis, 2001, Mammalian mitogen-activated protein kinase signal transduction pathways activated by stress and inflammation, Physiol. Rev., 81, 807, 10.1152/physrev.2001.81.2.807 Lee, 1994, A protein kinase involved in the regulation of inflammatory cytokine biosynthesis, Nature, 372, 739, 10.1038/372739a0 Tak, 2001, NF-κB: a key role in inflammatory diseases, J. Clin. Invest., 107, 7, 10.1172/JCI11830 Pearson, 2001, Mitogen-activated protein (MAP) kinase pathways: regulation and physiological functions, Endocr. Rev., 22, 153, 10.1210/er.22.2.153 Raingeaud, 1996, MKK3- and MKK6-regulated gene expression is mediated by the p38 mitogen activated protein kinase signal transduction pathway, Mol. Cell. Biol., 16, 1247, 10.1128/MCB.16.3.1247 Armant, 2002, Toll-like receptors: a family of pattern-recognition receptors in mammals, Genome Biol., 3, 3011.1, 10.1186/gb-2002-3-8-reviews3011 Badger, 1996, Pharmacological profile of SB 203580, a selective inhibitor of cytokine suppressive binding protein/p38 kinase, in animal models of arthritis, bone resorption, endotoxin shock, and immune function, J. Pharmacol. Exp. Ther., 279, 1453 Griswold, 1996, Pharmacology of cytokine suppressive antiinflammatory drug binding protein (CSBP), a novel stress-induced kinase, Pharmacol. Commun., 7, 323 Tong, 1997, A highly specific inhibitor of human p38 MAP kinase binds in the ATP pocket, Nat. Struct. Biol., 4, 311, 10.1038/nsb0497-311 Gum, 1998, Acquisition of sensitivity of stress activated protein kinases to the p38 inhibitor, SB 203580, by alteration of one or more amino acids within the ATP binding pocket, J. Biol. Chem., 273, 15605, 10.1074/jbc.273.25.15605 Frantz, 1998, The activation state of p38 mitogen-activated protein kinase determines the efficiency of ATP competition for pyridinylimidazole inhibitor binding, Biochemistry, 37, 13846, 10.1021/bi980832y Manthey, 1998, SB202190, a selective inhibitor of p38 mitogen-activated protein kinase, is a powerful regulator of LPS-induced mRNAs in monocytes, J. Leukoc. Biol., 64, 409, 10.1002/jlb.64.3.409 Lee, 1999, p38 mitogen-activated protein kinase inhibitors-mechanisms and therapeutic potentials, Pharmacol. Ther., 82, 389, 10.1016/S0163-7258(99)00008-X Saklatvala, 2003, Control of the expression of inflammatory response genes, Biochem. Soc. Symp., 70, 95, 10.1042/bss0700095 Hommes, 2003, Mitogen activated protein (MAP) kinase signal transduction pathways and novel anti-inflammatory targets, Gut, 52, 144, 10.1136/gut.52.1.144 Baldassare, 1999, The role of p38 mitogen-activated protein kinase in IL-1β transcription, J. Immunol., 162, 5367 Saccani, 2002, p38-dependent marking of inflammatory genes for increased NF-κB recruitment, Nat. Immunol., 3, 69, 10.1038/ni748 Shakhov, 1990, kB-type enhancers are involved in lipopolysaccharide-mediated transcriptional activation of the tumor necrosis factor α gene in primary macrophages, J. Exp. Med., 171, 35, 10.1084/jem.171.1.35 Yao, 1997, Lipopolysaccharide induction of the tumor necrosis factor-α promoter in human monocytic cells, regulation by Egr-1, c-Jun, and NFκB transcription factors, J. Biol. Chem., 272, 17795, 10.1074/jbc.272.28.17795 Zagariya, 1998, Tumor necrosis factor alpha gene regulation: enhancement of C/EBPβ-induced activation by c-Jun, Mol. Cell. Biol., 18, 2815, 10.1128/MCB.18.5.2815 Novotny, 1998, Nrf1 in a complex with fosB, c-jun, junD and ATF2 forms the AP1 component at the TNF-α promoter in stimulated mast cells, Nucleic Acids Res., 26, 5480, 10.1093/nar/26.23.5480 Yang, 1999, Targeting of p38 mitogen-activated protein kinases to MEF2 transcription factors, Mol. Cell. Biol., 19, 4028, 10.1128/MCB.19.6.4028 Wang, 1996, Stress-induced phosphorylation and activation of the transcription factor CHOP (GADD153) by p38 MAP kinase, Science, 272, 1347, 10.1126/science.272.5266.1347 Vermeulen, 2003, Transcriptional activation of the NF-κB p65 subunit by mitogen- and stress-activated protein kinase-1 (MSK1), EMBO J., 22, 1313, 10.1093/emboj/cdg139 Carter, 1999, The p38 mitogen-activated protein kinase is required for NF-κB-dependent gene expression, the role of TATA-binding protein (TBP), J. Biol. Chem., 274, 30858, 10.1074/jbc.274.43.30858 Campbell, 2004, A novel mechanism for TNF-α regulation by p38 MAPK: involvement of NF-κB with implications for therapy in rheumatoid arthritis, J. Immunol., 173, 6928, 10.4049/jimmunol.173.11.6928 Caput, 1986, Identification of a common nucleotide sequence in the 3′-untranslated region of mRNA molecules specifying inflammatory mediators, Proc. Natl. Acad. Sci. U. S. A., 83, 1670, 10.1073/pnas.83.6.1670 Winzen, 1999, The p38 MAP kinase pathway signals for cytokine-induced mRNA stabilization via MAP kinase-activated protein kinase 2 and an AU-rich region-targeted mechanism, EMBO J., 18, 4969, 10.1093/emboj/18.18.4969 Kontoyiannis, 1999, Impaired on/off regulation of TNF biosynthesis in mice lacking TNF AU-rich elements: implications for joint and gut associated immunopathologies, Immunity, 10, 387, 10.1016/S1074-7613(00)80038-2 Grzybowska, 2001, Regulatory functions of 3′ UTRs, Biochem. Biophys. Res. Commun., 288, 291, 10.1006/bbrc.2001.5738 Xu, 1997, Modulation of the fate of cytoplasmic mRNA by AU-rich elements: key sequence features controlling mRNA deadenylation and decay, Mol. Cell. Biol., 17, 4611, 10.1128/MCB.17.8.4611 Neininger, 2002, MK2 targets AU-rich elements and regulates biosynthesis of tumor necrosis factor and interleukin-6 independently at different post-transcriptional levels, J. Biol. Chem., 277, 3065, 10.1074/jbc.C100685200 Kotlyarov, 1999, MAPKAP kinase 2 is essential for LPS-induced TNF-α biosynthesis, Nat. Cell Biol., 1, 94, 10.1038/10061 Holtmann, 1999, Induction of interleukin-8 synthesis integrates effects on transcription and mRNA degradation from at least three different cytokine- or stress-activated signal transduction pathways, Mol. Cell. Biol., 19, 6675, 10.1128/MCB.19.10.6742 Holtmann, 2001, The MAP kinase kinase TAK1 plays a central role in coupling the interleukin-1 receptor to both transcriptional and RNA-targeted mechanisms of gene regulation, J. Biol. Chem., 276, 3508, 10.1074/jbc.M004376200 Beyaert, 1996, The p38/RK mitogen-activated protein kinase pathway regulates interleukin-6 synthesis response to tumor necrosis factor, EMBO J., 15, 1914, 10.1002/j.1460-2075.1996.tb00542.x Miyazawa, 1998, Regulation of interleukin-1β-induced interleukin-6 gene expression in human fibroblast-like synoviocytes by p38 mitogen-activated protein kinase, J. Biol. Chem., 273, 24832, 10.1074/jbc.273.38.24832 Hibbs, 1987, Macrophage cytotoxicity: role for l-arginine deiminase and imino nitrogen oxidation to nitrite, Science, 235, 473, 10.1126/science.2432665 Da Silva, 1997, Blockade of p38 mitogen activated protein kinase pathway inhibits inducible nitric-oxide synthase expression in mouse astrocytes, J. Biol. Chem., 272, 28373, 10.1074/jbc.272.45.28373 Chan, 1999, Evaluation of the role of mitogen-activated protein kinases in the expression of inducible nitric oxide synthase by IFN-γ and TNF-α in mouse macrophages, J. Immunol., 162, 415 Chen, 1999, p38 but not p44/42 mitogen-activated protein kinase is required for nitric oxide synthase induction mediated by lipopolysaccharide in RAW 264.7 macrophages, Mol. Pharmacol., 55, 481 Lowenstein, 1993, Macrophage nitric oxide synthase gene: two upstream regions mediate induction by interferon γ and lipopolysaccharide, Proc. Natl. Acad. Sci. U. S. A., 90, 9730, 10.1073/pnas.90.20.9730 Xie, 1994, Role of transcription factor NF-κB/Rel in induction of nitric oxide synthase, J. Biol. Chem., 269, 4705, 10.1016/S0021-9258(17)37600-7 Jackson, 1998, Pharmacological effects of SB 220025, a selective inhibitor of P38 mitogen-activated protein kinase, in angiogenesis and chronic inflammatory disease models, J. Pharmacol. Exp. Ther., 284, 687 Badger, 2000, Disease-modifying activity of SB 242235, a selective inhibitor of p38 mitogen-activated protein kinase, in rat adjuvant-induced arthritis, Arthritis Rheum., 43, 175, 10.1002/1529-0131(200001)43:1<175::AID-ANR22>3.0.CO;2-S Wada, 2005, R-130823, a novel inhibitor of p38 MAPK, ameliorates hyperalgesia and swelling in arthritis models, Eur. J. Pharmacol., 506, 285, 10.1016/j.ejphar.2004.11.013 Revesz, 2004, Novel p38 inhibitors with potent oral efficacy in several models of rheumatoid arthritis, Bioorg. Med. Chem. Lett., 14, 3595, 10.1016/j.bmcl.2004.03.106 Brown, 2004, A novel series of p38 MAP kinase inhibitors for the potential treatment of rheumatoid arthritis, Bioorg. Med. Chem. Lett., 14, 5383, 10.1016/j.bmcl.2004.08.006 Wadsworth, 1999, RWJ 67657, a potent, orally active inhibitor of p38 mitogen-activated protein kinase, J. Pharmacol. Exp. Ther., 291, 680 Branger, 2002, Anti-inflammatory effects of a p38 mitogen-activated protein kinase inhibitor during human endotoxemia, J. Immunol., 168, 4070, 10.4049/jimmunol.168.8.4070 Waetzig, 2002, p38 mitogen-activated protein kinase is activated and linked to TNF-alpha signaling in inflammatory bowel disease, J. Immunol., 168, 5342, 10.4049/jimmunol.168.10.5342 Hollenbach, 2004, Inhibition of p38 MAP kinase- and RICK/NF-kappaB-signaling suppresses inflammatory bowel disease, FASEB J., 18, 1550, 10.1096/fj.04-1642fje Hommes, 2002, Inhibition of stress-activated MAP kinases induces clinical improvement in moderate to severe Crohn's disease, Gastroenterology, 122, 7, 10.1053/gast.2002.30770 Sugino, 2000, Activation of mitogen-activated protein kinases after transient forebrain ischemia in gerbil hippocampus, J. Neurosci., 20, 4506, 10.1523/JNEUROSCI.20-12-04506.2000 Legos, 2001, SB 239063, a novel p38 inhibitor, attenuates early neuronal injury following ischemia, Brain Res., 892, 70, 10.1016/S0006-8993(00)03228-5 Barone, 2001, SB 239063, a second-generation p38 mitogen activated protein kinase inhibitor, reduces brain injury and neurological deficits in cerebral focal ischemia, J. Pharmacol. Exp. Ther., 296, 312 Barone, 2001, Inhibition of p38 mitogen-activated protein kinase provides neuroprotection in cerebral focal ischemia, Med. Res. Rev., 21, 129, 10.1002/1098-1128(200103)21:2<129::AID-MED1003>3.0.CO;2-H Piao, 2003, Administration of the p38 MAPK inhibitor SB203580 affords brain protection with a wide therapeutic window against focal ischemic insult, J. Neurosci. Res., 73, 537, 10.1002/jnr.10671 McDonald, 1998, Beta-amyloid fibrils activate parallel mitogen-activated protein kinase pathways in microglia and THP1 monocytes, J. Neurosci., 18, 4451, 10.1523/JNEUROSCI.18-12-04451.1998 McGeer, 1996, Arthritis and antiinflammatory agents as possible protective factors for Alzheimer's disease: a review of 17 epidemiologic studies, Neurology, 47, 425, 10.1212/WNL.47.2.425 Koistinaho, 2002, Beta-amyloid precursor protein transgenic mice that harbor diffuse A beta deposits but do not form plaques show increased ischemic vulnerability: role of inflammation, Proc. Natl. Acad. Sci. U. S. A., 99, 1610, 10.1073/pnas.032670899 Maroney, 2001, Cep-1347 (KT7515), a semisynthetic inhibitor of the mixed lineage kinase family, J. Biol. Chem., 276, 25302, 10.1074/jbc.M011601200 Maroney, 1998, Motoneuron apoptosis is blocked by CEP-1347 (KT 7515), a novel inhibitor of the JNK signaling pathway, J. Neurosci., 18, 104, 10.1523/JNEUROSCI.18-01-00104.1998 Saporito, 1999, CEP-1347/KT-7515, an inhibitor of c-jun N-terminal kinase activation, attenuates the 1-methyl-4-phenyl tetrahydropyridine-mediated loss of nigrostriatal dopaminergic neurons in vivo, J. Pharmacol. Exp. Ther., 288, 421 Lund, 2005, Inhibition of microglial inflammation by the MLK inhibitor CEP-1347, J. Neurochem., 92, 1439, 10.1111/j.1471-4159.2005.03014.x Han, 2001, c-Jun N-terminal kinase is required for metalloproteinase expression and joint destruction in inflammatory arthritis, J. Clin. Invest., 108, 73, 10.1172/JCI12466 Bogoyevitch, 2004, Targeting the JNK MAPK cascade for inhibition: basic science and therapeutic potential, Biochem. Biophys. Acta, 1697, 89, 10.1016/j.bbapap.2003.11.016 Cohen, 1996, CNI-1493 inhibits monocyte/macrophage tumor necrosis factor by suppression of translation efficiency, Proc. Natl. Acad. Sci. U. S. A., 93, 3967, 10.1073/pnas.93.9.3967 Bianchi, 1996, Suppression of pro-inflammatory cytokines in monocytes by a tetravalent guanylhydrazone, J. Exp. Med., 183, 927, 10.1084/jem.183.3.927 Bianchi, 1995, An inhibitor of macrophage arginine transport and nitric oxide production (CNI-1493) prevents acute inflammation and endotoxin lethality, Mol. Med., 1, 254, 10.1007/BF03401550 Kerlund, 1999, Anti-inflammatory effects of a new tumour necrosis factor-alpha (TNF-alpha) inhibitor (CNI-1493) in collagen-induced arthritis (CIA) in rats, Clin. Exp. Immunol., 115, 32, 10.1046/j.1365-2249.1999.00750.x Liu, 1991, Calcineurin is a common target of cyclophilin–cyclosporin A and FKBP–FK506 complexes, Cell, 66, 807, 10.1016/0092-8674(91)90124-H Shibasaki, 2002, Calcineurin as a multifunctional regulator, J. Biochem., 131, 1, 10.1093/oxfordjournals.jbchem.a003063 Guo, 2001, Neuroimmunophilines: novel neuroprotective and neurodegenerative targets, Ann. Neurol., 50, 6, 10.1002/ana.1030 Kaminska, 2004, Molecular mechanisms of neuroprotective action of immunosuppressants—facts and hypotheses, J. Cell. Mol. Med., 8, 45, 10.1111/j.1582-4934.2004.tb00259.x Zawadzka, 2005, A novel mechanism of FK506 mediated neuroprotection: down-regulation of cytokine expression in glial cells, Glia, 49, 36, 10.1002/glia.20092 Zawadzka, 2003, Immunosuppressant FK506 affects multiple signalling pathways and modulates gene expression in astrocytes, Mol. Cell. Neurosci., 22, 202, 10.1016/S1044-7431(03)00036-8 Lichtiger, 1994, Cyclosporine in severe ulcerative colitis refractory to steroid therapy, N. Engl. J. Med., 330, 1841, 10.1056/NEJM199406303302601 Egan, 1998, Clinical outcome following treatment of refractory inflammatory and fistulizing Crohn's disease with intravenous cyclosporine A, Am. J. Gastroenterol., 93, 442, 10.1111/j.1572-0241.1998.00442.x Rafiee, 2002, Cyclosporine A enhances leukocyte binding by human intestinal microvascular endothelial cells through inhibition of p38 MAPK and iNOS, J. Biol. Chem., 277, 35605, 10.1074/jbc.M205826200 Matsuda, 2000, Two distinct action mechanisms of immunophilin–ligand complexes for the blockade of T-cell activation, EMBO Rep., 1, 428, 10.1093/embo-reports/kvd090 Kumar, 2003, p38 MAP kinases: key signalling molecules as therapeutic targets for inflammatory diseases, Nat. Rev., Drug Discov., 2, 717, 10.1038/nrd1177 Underwood, 2000, SB 239063, a potent p38 MAP kinase inhibitor reduced inflammatory cytokine production, airways eosinophil infiltration and persistence, J. Pharmacol. Exp. Ther., 293, 281 Thurmond, 2001, Kinetics of small molecule inhibitors binding to p38 kinase, Eur. J. Biochem., 268, 5747, 10.1046/j.0014-2956.2001.02512.x